IL6 and COVID-19: With these trials, baricitinib joins a small set of other anti‐inflammatory drugs, such as the anti‐IL‐6 and IL‐6R monoclonal antibodies tocilizumab and sarilumab, and the corticosteroid dexamethasone, as a leading candidate therapy for severe COVID‐19 (Cox, 2020).